

**BAXTER INTERNATIONAL INC.**  
**Key Product Line Sales**  
**Periods Ending March 31, 2010 and 2009**  
**(unaudited)**  
**(\$ in millions)**

	Q1 2010	Q1 2009	% Growth @ Actual Rates	% Growth @ Constant Rates
<b>BioScience</b>				
Recombinants \$510		\$451	13%	8%
Plasma Proteins	292	274	7% (1%)	
Antibody Therapy	322	337	(4%)	(7%)
Regenerative Medicine	119	99	20%	14%
Other <sup>1</sup>	119	91	31%	20%
<b>Total BioScience</b>	<b>\$1,362</b>	<b>\$1,252</b>	<b>9%</b>	<b>3%</b>
<b>Medication Delivery</b>				
IV Therapies	\$391	\$344	14%	6%
Global Injectables	451	371	22%	14%
Infusion Systems	209	199	5%	(1%)
Anesthesia	127	109	17%	11%
Other <sup>4</sup>		12	(67%)	(50%)
<b>Total Medication Delivery</b>	<b>\$1,182</b>	<b>\$1,035</b>	<b>14%</b>	<b>8%</b>
<b>Renal</b>				
PD Therapy	\$474	\$420	13%	5%
HD Therapy	110	95	16%	5%
<b>Total Renal</b>	<b>\$584</b>	<b>\$515</b>	<b>13%</b>	<b>5%</b>
<b>Baxter excluding Transfusion Therapies</b>	<b>\$3,128</b>	<b>\$2,802</b>	<b>12%</b>	<b>5%</b>
<b>Transfusion Therapies <sup>2</sup></b>	<b>\$12</b>	<b>\$22</b>	<b>(45%)</b>	<b>(45%)</b>
<b>Total Baxter</b>	<b>\$3,140</b>	<b>\$2,824</b>	<b>11%</b>	<b>5%</b>

<sup>1</sup> Principally includes vaccines and sales of plasma to third parties.

<sup>2</sup> Represents revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the TT business after the February 2007 divestiture.